Merz and Acumen agree Alzheimer's disease collaboration
This article was originally published in Scrip
Executive Summary
Acumen Pharmaceuticals, a biotech company focused on Alzheimer's disease, has licensed a drug development programme and related technology to the German neurological and psychiatric drug developer, Merz Pharmaceuticals, for an undisclosed amount.